Avacopan is a medication used in the treatment of ANCA-associated vasculitis, which is a rare autoimmune condition affecting blood vessels. This medication works by blocking a specific protein involved in inflammation, helping to reduce the symptoms of vasculitis. It is taken orally and represents an alternative to traditional treatments for this condition.

Note: This is a Phase 4 clinical trial studying the long-term effects of the medication, which means the drug has already been approved for use but is being studied further to understand its long-term safety and effectiveness.

Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) – A rare autoimmune condition where the body’s immune system attacks its own blood vessels, causing inflammation and damage. The disease can affect small and medium-sized blood vessels throughout the body, particularly in the kidneys, lungs, skin, and nerves. AAV develops when harmful antibodies called ANCAs (antineutrophil cytoplasmic antibodies) mistakenly target certain white blood cells, leading to blood vessel inflammation. The condition typically progresses gradually, with symptoms varying depending on which organs are affected. The inflammation can cause the blood vessel walls to thicken, reducing blood flow to various organs and tissues.